{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:12:13Z","timestamp":1792638733667,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:00:00Z","timestamp":1784332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024370","name":"Ministero dell'Istruzione dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108348","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:39:23Z","timestamp":1784561963000},"page":"108348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeting ATP-citrate lyase across cardiometabolic and oncologic disease"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5919-989X","authenticated-orcid":false,"given":"Chiara","family":"Macchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-6321","authenticated-orcid":false,"given":"Silvia","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7087-5553","authenticated-orcid":false,"given":"Serena","family":"Ghisletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-3619","authenticated-orcid":false,"given":"Nico","family":"Mitro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-7061","authenticated-orcid":false,"given":"Massimiliano","family":"Ruscica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.phrs.2026.108348_bib1","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","article-title":"Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome","volume":"45","author":"Cramer","year":"2004","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2026.108348_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.phrs.2026.108348_bib4","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/cvr\/cvac020","article-title":"Side effects of statins: from pathophysiology and epidemiology to diagnostic and therapeutic implications","volume":"118","author":"Ruscica","year":"2023","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108348_bib5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s10557-023-07474-9","article-title":"The clinical efficacy and safety of bempedoic acid in patients at elevated risk of cardiovascular disease: a meta-analysis of randomized clinical trials","volume":"38","author":"Sayed","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"15","key":"10.1016\/j.phrs.2026.108348_bib6","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Investigators CO. Bempedoic Acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2026.108348_bib7","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.tem.2025.04.002","article-title":"Molecular targets of bempedoic acid and related decoy fatty acids","volume":"36","author":"Supplee","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2026.108348_bib8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2026.108348_bib9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.cmet.2025.09.011","article-title":"The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARalpha","volume":"37","author":"Xie","year":"2025","journal-title":"Cell. Metab."},{"issue":"8080","key":"10.1016\/j.phrs.2026.108348_bib10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-025-09297-0","article-title":"ACLY inhibition promotes tumour immunity and suppresses liver cancer","volume":"645","author":"Gautam","year":"2025","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2026.108348_bib11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.cmet.2025.12.018","article-title":"Bempedoic acid directly binds and activates PPARalpha","volume":"38","author":"Papa","year":"2026","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12915-025-02423-4","article-title":"TCA-cycle metabolites in the nucleus: drivers of chromatin and epigenetic control","volume":"23","author":"Ghisletti","year":"2025","journal-title":"BMC Biol."},{"key":"10.1016\/j.phrs.2026.108348_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117684","article-title":"Design, synthesis, and Biological evaluation of novel macrocyclic derivatives as potent ATP-citrate lyase inhibitors","volume":"292","author":"Zang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"7753","key":"10.1016\/j.phrs.2026.108348_bib14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41586-019-1095-5","article-title":"Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle","volume":"568","author":"Verschueren","year":"2019","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.phrs.2026.108348_bib15","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S0021-9258(19)40033-1","article-title":"Rat ATP citrate-lyase. Molecular cloning and sequence analysis of a full-length cDNA and mRNA abundance as a function of diet, organ, and age","volume":"265","author":"Elshourbagy","year":"1990","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2012.04.144","article-title":"ATP-citrate lyase: a mini-review","volume":"422","author":"Chypre","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"25","key":"10.1016\/j.phrs.2026.108348_bib17","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1021\/bi300611s","article-title":"On the catalytic mechanism of human ATP citrate lyase","volume":"51","author":"Fan","year":"2012","journal-title":"Biochemistry"},{"issue":"5930","key":"10.1016\/j.phrs.2026.108348_bib18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cell.2014.04.046","article-title":"A nuclear pyruvate dehydrogenase complex is important for the generation of acetyl-CoA and histone acetylation","volume":"158","author":"Sutendra","year":"2014","journal-title":"Cell"},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108348_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.cell.2016.12.026","article-title":"Nuclear localization of mitochondrial TCA cycle enzymes as a critical step in mammalian zygotic genome activation","volume":"168","author":"Nagaraj","year":"2017","journal-title":"Cell"},{"issue":"7684","key":"10.1016\/j.phrs.2026.108348_bib21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nature25003","article-title":"KAT2A coupled with the alpha-KGDH complex acts as a histone H3 succinyltransferase","volume":"552","author":"Wang","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2026.108348_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41588-017-0026-3","article-title":"Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer","volume":"50","author":"Chen","year":"2018","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.phrs.2026.108348_bib23","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1002\/jcp.30355","article-title":"Acetyl-CoA synthases are essential for maintaining histone acetylation under metabolic stress during zygotic genome activation in pigs","volume":"236","author":"Zhou","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2026.108348_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1272646","article-title":"Novel insights into the role of acetyl-CoA producing enzymes in epigenetic regulation","volume":"14","author":"Russo","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/j.phrs.2026.108348_bib25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.molcel.2023.12.033","article-title":"Acetyl-CoA production by Mediator-bound 2-ketoacid dehydrogenases boosts de novo histone acetylation and is regulated by nitric oxide","volume":"84","author":"Russo","year":"2024","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41419-025-08300-w","article-title":"ACSS1 co-opts acetyl-CoA metabolism to drive DNA repair and undermine radiotherapy efficacy in breast cancer","volume":"17","author":"Fu","year":"2025","journal-title":"Cell. Death Dis."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2026.108348_bib27","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1042\/bj3340113","article-title":"The role of ATP citrate-lyase in the metabolic regulation of plasma lipids. Hypolipidaemic effects of SB-204990, a lactone prodrug of the potent ATP citrate-lyase inhibitor SB-201076","volume":"334","author":"Pearce","year":"1998","journal-title":"Biochem. J."},{"issue":"11","key":"10.1016\/j.phrs.2026.108348_bib28","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1016\/j.bmcl.2007.03.017","article-title":"2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors","volume":"17","author":"Li","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2026.108348_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.914865","article-title":"ATP-citrate lyase inhibitor improves ectopic lipid accumulation in the kidney in a db\/db mouse model","volume":"13","author":"Zhan","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"7753","key":"10.1016\/j.phrs.2026.108348_bib30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41586-019-1094-6","article-title":"An allosteric mechanism for potent inhibition of human ATP-citrate lyase","volume":"568","author":"Wei","year":"2019","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2026.108348_bib31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.apsb.2022.06.011","article-title":"Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia","volume":"13","author":"Xie","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.phrs.2026.108348_bib32","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1016\/j.apsb.2024.10.008","article-title":"Aclysiran, an RNAi therapeutic agent targeting ACLY, treats hypercholesterolemia and atherosclerosis in ApoE (-\/-) mice","volume":"14","author":"Chen","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.phrs.2026.108348_bib33","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1039\/D5NA00094G","article-title":"Hydroxycitrate-loaded exosomes demonstrate enhanced therapeutic efficacy against lung adenocarcinoma by inhibiting the metabolic enzyme ATP citrate lyase","volume":"7","author":"Phutela","year":"2025","journal-title":"Nanoscale Adv."},{"issue":"10","key":"10.1016\/j.phrs.2026.108348_bib34","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.7150\/thno.105782","article-title":"A natural small molecule isoginkgetin alleviates hypercholesterolemia and atherosclerosis by targeting ACLY","volume":"15","author":"Zhang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2026.108348_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118796","article-title":"Design and synthesis of novel ATP-citrate lyase inhibitors and their effects on MAFLD\/MASH","volume":"310","author":"Xu","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"10","key":"10.1016\/j.phrs.2026.108348_bib36","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic acid: for whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"issue":"44","key":"10.1016\/j.phrs.2026.108348_bib37","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1093\/eurheartj\/ehaf606","article-title":"The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications","volume":"46","author":"Ballantyne","year":"2025","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.phrs.2026.108348_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100086","article-title":"The evolution of lipid-lowering drugs in the management of cardiovascular disease risk: from the first cardiovascular disease risk-reducing therapies to the novel challenging strategies","volume":"77","author":"Henry","year":"2025","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2026.108348_bib39","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jacl.2026.02.006","article-title":"Low-density lipoprotein cholesterol lowering and risk of major adverse cardiovascular events in primary prevention trials: a meta-analysis","volume":"20","author":"Kalra","year":"2026","journal-title":"J. Clin. Lipidol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108348_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2026.100140","article-title":"Are we underestimating the benefits of lipid-lowering therapies?","volume":"78","author":"Pirillo","year":"2026","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.phrs.2026.108348_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.phrs.2026.108348_bib42","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2024.03.390","article-title":"Characteristics and outcomes for hispanic\/latinx participants with statin intolerance receiving bempedoic acid","volume":"83","author":"Rodriguez","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"22","key":"10.1016\/j.phrs.2026.108348_bib43","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1161\/CIRCULATIONAHA.123.067691","article-title":"Impact of bempedoic acid on cardiovascular outcomes by sex","volume":"149","author":"Cho","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2026.108348_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120479","article-title":"2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"409","author":"Mach","year":"2025","journal-title":"Atherosclerosis"},{"issue":"17","key":"10.1016\/j.phrs.2026.108348_bib45","first-page":"e1154","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Writing Committee","year":"2026","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.phrs.2026.108348_bib46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108348_bib47","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","article-title":"Comparative cardiovascular benefits of bempedoic acid and statin drugs","volume":"84","author":"Lincoff","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108348_bib48","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011295","article-title":"Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults","volume":"8","author":"Raghavan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Committees CO, Investigators. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib50","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-026-03185-1","article-title":"The role of bempedoic acid in the management of dyslipidaemia in people with diabetes: an expert opinion of Italian diabetologists","volume":"25","author":"Federici","year":"2026","journal-title":"Cardiovasc. Diabetol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108348_bib51","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.037898","article-title":"Bempedoic acid for prevention of cardiovascular events in people with obesity: a CLEAR outcomes subset analysis","volume":"14","author":"Bays","year":"2025","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2026.108348_bib52","article-title":"Obesity, diabetes mellitus, and cardiometabolic risk: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023","volume":"5","author":"Bays","year":"2023","journal-title":"Obes. Pillars"},{"key":"10.1016\/j.phrs.2026.108348_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2026.04.015","article-title":"Lipid and anti-inflammatory effects of bempedoic acid across treatment regimens: a harmonized meta-analysis of randomized trials","author":"Al Kayed","year":"2026","journal-title":"J. Clin. Lipidol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108348_bib54","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2026.108348_bib55","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwag102","article-title":"Effect of bempedoic acid on cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","author":"de Jong","year":"2026","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2026.108348_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2026.1208","article-title":"Bempedoic acid and venous thromboembolism risk among statin-intolerant patients: a post hoc analysis of the CLEAR outcomes randomized clinical trial","author":"Spiazzi","year":"2026","journal-title":"JAMA Cardiol."},{"issue":"11 Pt 1","key":"10.1016\/j.phrs.2026.108348_bib57","article-title":"Association of uric acid-lowering therapies on gout frequency with bempedoic acid: clinical insights from CLEAR outcomes","volume":"4","author":"Ray","year":"2025","journal-title":"JACC Adv."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib58","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jacl.2023.10.011","article-title":"Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance","volume":"18","author":"Bays","year":"2024","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2026.108348_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2026.101056","article-title":"Bempedoic acid within the phase ternary diagram governing biliary cholesterol solubilization and gallstone risk","author":"Di Ciaula","year":"2026","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2026.108348_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106900","article-title":"Mechanism of bempedoic acid induced cholelithiasis: a role for statins to limit this adverse effect?","volume":"196","author":"Ferri","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108348_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118726","article-title":"Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE(-\/-) mice","volume":"193","author":"Macchi","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.phrs.2026.108348_bib62","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jfma.2022.03.001","article-title":"2022 focused update of the 2017 Taiwan lipid guidelines for high risk patients: coronary artery disease, peripheral artery disease and ischemic stroke","volume":"121","author":"Chen","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"issue":"12","key":"10.1016\/j.phrs.2026.108348_bib63","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.jfma.2022.05.010","article-title":"expert committee for the Taiwan Lipid Guidelines for Primary P. 2022 Taiwan lipid guidelines for primary prevention","volume":"121","author":"Huang","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"issue":"10","key":"10.1016\/j.phrs.2026.108348_bib64","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.126.049917","article-title":"Effectiveness and safety of bempedoic acid in Taiwanese patients with hypercholesterolemia: a pragmatic phase 4 study (CLEAR Taiwan Study)","volume":"15","author":"Hsieh","year":"2026","journal-title":"J. Am. Heart Assoc."},{"issue":"9","key":"10.1016\/j.phrs.2026.108348_bib65","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Committee for E, Clinical Management of A. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"issue":"4","key":"10.1016\/j.phrs.2026.108348_bib66","doi-asserted-by":"crossref","first-page":"449","DOI":"10.5551\/jat.65947","article-title":"Long-term safety and efficacy of bempedoic acid in Japanese patients with hypercholesterolemia: the CLEAR-J LONG","volume":"33","author":"Masuda","year":"2026","journal-title":"J. Atheroscler. Thromb."},{"issue":"6","key":"10.1016\/j.phrs.2026.108348_bib67","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.jacl.2025.09.033","article-title":"Clinical implementation of bempedoic acid in blood lipid management: real-world data from an Italian lipid clinic","volume":"19","author":"Pavanello","year":"2025","journal-title":"J. Clin. Lipidol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108348_bib68","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jacl.2026.02.014","article-title":"Bempedoic acid vs ezetimibe added to statin therapy: Cardiovascular outcomes in the real-world-The BEYOND-REAL Study","volume":"20","author":"White","year":"2026","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2026.108348_bib69","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf777","article-title":"Oral triple combination lipid-lowering therapy and LDL cholesterol goal attainment: a simulation using the SANTORINI study cohort","author":"Katzmann","year":"2025","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jacl.2025.11.010","article-title":"From clinical inertia to therapeutic optimization in patients with atherosclerotic cardiovascular disease: a Monte Carlo simulation within the ITACARE-P registry","volume":"20","author":"Faggiano","year":"2026","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108348_bib71","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1161\/CIRCULATIONAHA.125.075388","article-title":"Triple versus dual lipid-lowering therapy in acute coronary syndrome: the ES-BempedACS Randomized Clinical Trial","volume":"153","author":"Raposeiras-Roubin","year":"2026","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.phrs.2026.108348_bib72","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ehjcvp\/pvab064","article-title":"Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response model","volume":"8","author":"Jadhav","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"10","key":"10.1016\/j.phrs.2026.108348_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102401","article-title":"Paradoxical activation of transcription factor SREBP1c and de novo lipogenesis by hepatocyte-selective ATP-citrate lyase depletion in obese mice","volume":"298","author":"Yenilmez","year":"2022","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib74","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cmet.2024.10.014","article-title":"Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase","volume":"37","author":"Liu","year":"2025","journal-title":"Cell. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cmet.2025.11.015","article-title":"Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH","volume":"38","author":"Di Pastena","year":"2026","journal-title":"Cell. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2026.108348_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117369","article-title":"CIDEB and CGI-58 differentially regulate liver lipid-droplet cholesterol to modulate metabolic dysfunction-associated steatohepatitis severity","volume":"45","author":"Sakuma","year":"2026","journal-title":"Cell. Rep."},{"issue":"10","key":"10.1016\/j.phrs.2026.108348_bib77","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1074\/jbc.M310512200","article-title":"ATP-citrate lyase deficiency in the mouse","volume":"279","author":"Beigneux","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2026.108348_bib78","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1194\/jlr.M003335","article-title":"Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in mice","volume":"51","author":"Wang","year":"2010","journal-title":"J. Lipid Res."},{"issue":"31","key":"10.1016\/j.phrs.2026.108348_bib79","doi-asserted-by":"crossref","first-page":"11805","DOI":"10.1074\/jbc.RA119.008708","article-title":"Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease","volume":"294","author":"Guo","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.phrs.2026.108348_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/genes15081059","article-title":"Effects of ACLY inhibition on body weight distribution: a drug target mendelian randomization study","volume":"15","author":"Gill","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.phrs.2026.108348_bib81","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-026-03209-w","article-title":"Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study","author":"Chen","year":"2026","journal-title":"Cardiovasc. Diabetol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108348_bib82","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease","volume":"380","author":"Ference","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2026.108348_bib83","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/ehjcvp\/pvae092","article-title":"Lipid-lowering therapies for aortic stenosis: a drug-target Mendelian randomization study","volume":"11","author":"Ciofani","year":"2025","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"4","key":"10.1016\/j.phrs.2026.108348_bib84","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.celrep.2016.09.069","article-title":"ATP-citrate lyase controls a glucose-to-acetate metabolic switch","volume":"17","author":"Zhao","year":"2016","journal-title":"Cell. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2026.108348_bib85","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s44161-024-00502-3","article-title":"Nuclear ATP-citrate lyase regulates chromatin-dependent activation and maintenance of the myofibroblast gene program","volume":"3","author":"Lazaropoulos","year":"2024","journal-title":"Nat. Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2026.108348_bib86","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2019.12.010","article-title":"ATP citrate lyase: A central metabolic enzyme in cancer","volume":"471","author":"Icard","year":"2020","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.phrs.2026.108348_bib87","doi-asserted-by":"crossref","DOI":"10.3390\/genes12091460","article-title":"Mammalian SIRT6 represses invasive cancer cell phenotypes through ATP Citrate Lyase (ACLY)-dependent histone acetylation","volume":"12","author":"Zheng","year":"2021","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.phrs.2026.108348_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2026.101314","article-title":"Metabolic regulation of histone acetylation by ACLY supports MDR1 expression in colorectal cancer and highlights a targetable vulnerability","volume":"77","author":"Garcia-Bautista","year":"2026","journal-title":"Neoplasia"},{"issue":"8098","key":"10.1016\/j.phrs.2026.108348_bib89","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41586-025-09745-x","article-title":"Cytosolic acetyl-coenzyme A is a signalling metabolite to control mitophagy","volume":"649","author":"Zhang","year":"2026","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2026.108348_bib90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.chembiol.2026.01.006","article-title":"Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesis","volume":"33","author":"Kim","year":"2026","journal-title":"Cell. Chem. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108348_bib91","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s43018-023-00635-7","article-title":"PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma","volume":"4","author":"Wartewig","year":"2023","journal-title":"Nat. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108348_bib92","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41419-024-06951-9","article-title":"Chemotherapy-induced acetylation of ACLY by NAT10 promotes its nuclear accumulation and acetyl-CoA production to drive chemoresistance in hepatocellular carcinoma","volume":"15","author":"Wang","year":"2024","journal-title":"Cell. Death Dis."},{"issue":"11","key":"10.1016\/j.phrs.2026.108348_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cells10112962","article-title":"ACLY nuclear translocation in human macrophages drives proinflammatory gene expression by NF-kappaB acetylation","volume":"10","author":"Santarsiero","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.phrs.2026.108348_bib94","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1186\/s12967-023-04431-w","article-title":"ACLY as a modulator of liver cell functions and its role in metabolic dysfunction-associated steatohepatitis","volume":"21","author":"Convertini","year":"2023","journal-title":"J. Transl. Med."},{"issue":"46","key":"10.1016\/j.phrs.2026.108348_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi8602","article-title":"Lactate supports a metabolic-epigenetic link in macrophage polarization","volume":"7","author":"Noe","year":"2021","journal-title":"Sci. Adv."},{"issue":"49","key":"10.1016\/j.phrs.2026.108348_bib96","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi2465","article-title":"Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation","volume":"9","author":"Xiang","year":"2023","journal-title":"Sci. Adv."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600263X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600263X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:03:52Z","timestamp":1789398232000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182600263X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":96,"alternative-id":["S104366182600263X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108348","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting ATP-citrate lyase across cardiometabolic and oncologic disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108348","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108348"}}